
News|Articles|September 1, 2003
Aloxi (Palonosetron)
5-HT3 receptor antagonist indicated to prevent delayed CINV
Advertisement
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Advertisement
Latest CME
Advertisement
Advertisement























